Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329823 | 0.91 | MAPK14 (0.50) | MAPK14CSNK1DCSNK1ECSNK1A1GRM5 | |
| SCHEMBL6178431 | 0.90 | MAPK14 (0.53) | MAPK14CSNK1DCSNK1ECSNK1A1GRM5 | |
| SCHEMBL6177916 | 0.85 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ECSNK1A1GRM5 | |
| SCHEMBL4335760 | 0.83 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1ECSNK1A1GRM5 | |
| SCHEMBL6179749 | 0.83 | MAPK14 (0.50) | MAPK14CSNK1DCSNK1EGRM5MAPT | |
| SCHEMBL4329207 | 0.83 | MAPK14 (0.50) | MAPK14CSNK1DCSNK1EGRM5MAPT | |
| SCHEMBL4343524 | 0.83 | PSEN1 (0.48) | MAPK14CSNK1DCSNK1ENAMPTCSNK1A1 | |
| SCHEMBL6177746 | 0.82 | MAPK14 (0.47) | MAPK14CSNK1DCSNK1ENAMPTCSNK1A1 | |
| SCHEMBL6178590 | 0.82 | MAPK14 (0.56) | MAPK14CSNK1DCSNK1ECSNK1A1GRM5 | |
| SCHEMBL4338469 | 0.82 | MAPK14 (0.49) | MAPK14CSNK1DCSNK1EGRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1142890-B1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6511997-B1 | For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-01-28 | — | — | US | disclosed |
| EP-1142890-A1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885CSNK1D 288/4885CSNK1E 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.